Peptide Based Hematological Disorders Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022

Introduction

Due to the advances in technology, the manufacturers and suppliers are encouraged to seek novel methods for peptide manufacturing, which is bound to improve the production of longer and complex chain of peptides and reduce the cost of production.

Moreover, due to the automation of instruments, with improvements in the purification process and reduction in the total waste generated, are the driving factors triggering the growth of the global peptide therapeutics market. However, the synthesis and purification of long peptides is challenging for the manufacturers.

Also, the rise in modifications and the addition of more unnatural amino acids have further increased the complications in peptide synthesis. This makes the manufactures of peptides difficult, and therefore the gap between demand and supply is increasing.

Also, the manufacturing of peptides is a costly process, which hampers the growth of the global peptide therapeutics market.

Haematological disorders are the disorders related to problems in blood and blood components such as red blood cells, white blood cells, platelets, blood vessels, lymph nodes, spleen, bone marrow and the problems related to the proteins involved in bleeding and clotting (haemostasis and thrombosis).

Therapeutic peptides are used in the treatment of haematological disorders mentioned above. Peptides are short chains of amino acid monomers linked by peptide (amide) bonds.

Such type of covalent chemical bonds are formed when the carboxyl group of one amino acid reacts with the amino group of another. Peptides are differentiated from proteins on the basis of size, and peptides contain 50 amino acids or less approximately.

This Fact.MR report on the global peptide based hematological disorders therapeutics market forecasts that the global peptide based hematological disorders therapeutics market will touch a value of nearly US$ 530 Mn in the year 2022 and grow at a robust CAGR during the assessment period.

North America Market Set to Dominate the Global Peptide Based Hematological Disorders Therapeutics Market in Terms of Revenue

The market in North America is set to dominate the global peptide based hematological disorders therapeutics market in terms of value and this trend is projected to sustain itself throughout the assessment period.

North America peptide based hematological disorders therapeutics market is the most attractive market, growing at a robust CAGR over the assessment period.

Icatibant Segment Poised to Touch a Value of Nearly US$ 410 Mn in 2022

As per the forecast of Fact.MR, the icatibant segment is expected to reach a value of nearly US$ 410 Mn in the year 2022. This represents a robust CAGR during the forecast period of 2017-2022.

Icatibant segment is expected to account for more than three-fourth of the revenue share of the drug segment by the year 2017 and is expected to lose market share by the end of the year 2022.

Hospital Pharmacies Segment to exhibit a CAGR of 7.4% During the Assessment Period

As per the forecast of Fact.MR, the hospital pharmacies segment is slated to touch a figure of nearly US$ 260 Mn in the year 2022. This represents a CAGR of 7.4% during the assessment period from 2017 till the year 2022. This segment is expected to lose market share by the end of the year 2022.

The hospital pharmacies segment is expected to account for more than half of the revenue share of the distribution channel segment by the year 2017.

Competition Tracking

The report also profiles companies that are expected to remain active in the expansion of global peptide based hematological disorders therapeutics market through 2022, which includes

• Shire plc.

Market Taxonomy

• By Drug :

  • Icatibant
  • Ecallantide

• By Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)